Biovac Signs Deal to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets

Biovac Signs Deal to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets.

23 NOVEMBER 2022 – South African based Bio-pharmaceutical company, Biovac, has concluded a ground-breaking licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organisation headquartered in South Korea, for the manufacture of an oral cholera vaccine (OCV).